title: [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2002). I. Susceptibility distribution].
abstract: The bacterial strains isolated from 491 patients diagnosed as having urinary tract infections (UTIs) in 13 institutions in Japan were supplied between August 2002 and July 2003. The susceptibilities of them to many kinds of antimicrobial agents were investigated. Of them, 578 strains were estimated as causative bacteria and used for the investigation. The number of them was 578 strains consisting of 177 gram-positive bacterial strains (30.6%) and 401 gram-negative bacterial strains (69.4%). Against Staphylococcus aureus, vancomycin (VCM) showed a strong activity and prevented the growth of all strains with 1 microg/mL. The susceptibility of Staphylococcus epidermidis to cephems including cefotiam (CTM) was relatively good. Against Enterococcus faecalis, ampicillin (ABPC), imipenem (IPM), and VCM showed the strongest antibacterial activity (MIC90: 2-4 microg/mL). In addition, the low sensitive strains (MIC: > or = 256 microg/mL) to clarithromycin (CAM) were detected at 48.3% but none to cefozopran (CZOP). The antibacterial activity of cephems to Escherichia coli was generally good, and especially CZOP and cefpirome (CPR) showed the highest activity (MIC90: < or = 0.125 microg/mL). Quinolone resistant E. coli was detected at frequency of 13.5%, which was higher than that in the last year. The antibacterial activity of cephems to Citrobacter freundii was generally low but CZOP and CPR had a strong acitivity (MIC90: 0.25 and 0.5 microg/mL, respectively). The antibacterial activity of cephems to Klebsiella pneumoniae was good and especially cefmenoxime (CMX), cefixime (CFIX), flomoxef (FMOX), CPR, and CZOP showed stronger activity (MIC90: < or = 0.125 microg/mL). Against Serratia marcescens, meropenem (MEPM) had the highest antibacterial activity followed by CPR and CZOP. Against Proteus mirabilis, CMX, ceftazidime (CAZ), CPR, MEPM, carumonam (CRMN), and levofloxacin (LVFX) showed the strongest activity (MC90: < or = 0.125 microg/mL). Among other cephems, CZOP and CFIX were also strong (MIC90: 0.25 microg/mL). The antibacterial activity of the drugs to Pseudomonas aeruginosa was generally low, and MIC90 of all the drugs were ranged from 64 to > or = 256 microg/mL except IPM and amikacin (AMK) having 16 microg/mL. The antibacterial activity of CZOP was relatively good (MIC50: 8 microg/mL).
authors.affiliation: Department of Urology, Sapporo Medical University School of Medicine.
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Kumamoto
authors.forename: Taiji
authors.initials: T
authors.lastname: Tsukamoto
authors.forename: Masanori
authors.initials: M
authors.lastname: Matsukawa
authors.forename: Yasuharu
authors.initials: Y
authors.lastname: Kunishima
authors.forename: Takaoki
authors.initials: T
authors.lastname: Hirose
authors.forename: Osamu
authors.initials: O
authors.lastname: Yamaguti
authors.forename: Kei
authors.initials: K
authors.lastname: Ishibashi
authors.forename: Shiro
authors.initials: S
authors.lastname: Shigeta
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Suzutani
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Yoshida
authors.forename: Yuuji
authors.initials: Y
authors.lastname: Imafuku
authors.forename: Masaru
authors.initials: M
authors.lastname: Murai
authors.forename: Kiyoaki
authors.initials: K
authors.lastname: Watanabe
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Kobayashi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Uchida
authors.forename: Seiji
authors.initials: S
authors.lastname: Matsuda
authors.forename: Shinichi
authors.initials: S
authors.lastname: Sato
authors.forename: Makoto
authors.initials: M
authors.lastname: Fujime
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Fujita
authors.forename: Jun
authors.initials: J
authors.lastname: Igari
authors.forename: Toyoko
authors.initials: T
authors.lastname: Oguri
authors.forename: Keizo
authors.initials: K
authors.lastname: Yamaguchi
authors.forename: Nobuhiko
authors.initials: N
authors.lastname: Furuya
authors.forename: Takashi
authors.initials: T
authors.lastname: Deguchi
authors.forename: Satoshi
authors.initials: S
authors.lastname: Ishihara
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ooe
authors.forename: Mineko
authors.initials: M
authors.lastname: Nishikawa
authors.forename: Toshitsugu
authors.initials: T
authors.lastname: Oka
authors.forename: Masaya
authors.initials: M
authors.lastname: Kitamura
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Fukuhara
authors.forename: Sadao
authors.initials: S
authors.lastname: Kamidono
authors.forename: Soichi
authors.initials: S
authors.lastname: Arakawa
authors.forename: Hiromi
authors.initials: H
authors.lastname: Kumon
authors.forename: Koichi
authors.initials: K
authors.lastname: Monden
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Matsumoto
authors.forename: Koichi
authors.initials: K
authors.lastname: Takahashi
authors.forename: Seiji
authors.initials: S
authors.lastname: Naito
authors.forename: Toshihisa
authors.initials: T
authors.lastname: Egashira
authors.forename: Shigeru
authors.initials: S
authors.lastname: Kohno
authors.forename: Yoshitsugu
authors.initials: Y
authors.lastname: Miyazaki
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Hirakata
authors.forename: Siho
authors.initials: S
authors.lastname: Aoki
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects* / Q000302:isolation & purification*; D024881:Drug Resistance, Bacterial; D006801:Humans; D013997:Time Factors; D014552:Urinary Tract Infections / Q000382:microbiology*
chemical_list: D000900:Anti-Bacterial Agents